News
On the horizon: Asciminib, a new drug for treating r/r CML
“Although we have many excellent therapies for CML, having a new medication that targets BCR-ABL in a novel way is still welcome to help us better...
News
Five-minute SC injection of daratumumab in RRMM
“The appeal of subcutaneous daratumumab is the 5 minutes it needs for administering, cutting down considerable on ‘chair/clinic’ time.”
News
Oral azacitidine: First maintenance therapy for AML
ORLANDO – Investigators called CC-486, an oral formulation of azacitidine, a “new therapeutic standard” for patients with acute myeloid leukemia...
News
Global burden of hematologic malignancies
Research has shown an increase in the global incidence of leukemia and non-Hodgkin lymphoma (NHL) in recent years. The Global Burden of Disease (...
News
Kinase may be therapeutic target for hemoglobinopathies
A kinase called heme-regulated inhibitor (HRI) could be a therapeutic target for sickle cell disease (SCD) and some forms of β-thalassemia,...
News
Breakthrough drugs approved with less stringent criteria
Clinical trials supporting the approval of drugs with breakthrough therapy designation1 do not meet the same standards as trials for non-...
News
PET-guided treatment didn’t improve outcomes
In the PETAL trial, treatment intensification based on results of an interim positron emission tomography (PET) scan did not improve survival...
News
Mutations linked to higher risk of SNs in CCSs
New research has shown that childhood cancer survivors (CCSs) with certain germline mutations have higher relative rates (RRs) of secondary...
News
Inhibitor could be repurposed for MM
Tofacitinib, a pan-JAK inhibitor approved to treat rheumatoid arthritis, may advance as a potential treatment for multiple myeloma (MM) based on...
News
Transplant strategy not viable for aggressive B-NHL
Transplant with radioimmunotherapy (RIT)-based conditioning is a viable treatment option for patients with indolent—but not aggressive—B-cell non-...
News
Group updates guidelines on CLL
Recent advances in chronic lymphocytic leukemia (CLL) have prompted an update to the 2008 International Workshop in Chronic Lymphocytic Leukemia (...
News
Ivosidenib active in R/R IDH1-mutated AML patients
CHICAGO—The investigational drug ivosidenib, an inhibitor of the mutant IDH1 enzyme, achieved complete remission (CR) rates of 32% and an overall...
News
Ibrutinib and venetoclax combo promising in frontline CLL
CHICAGO—Ibrutinib combined with venetoclax is showing promising clinical activity in the frontline treatment of patients with chronic lymphocytic...